Assessing treatment outcome: how do we interpret the data?

. 1999 Dec;1(2):157-8.

doi: 10.1007/s11920-999-0025-x.

G E Woody¹

Affiliations

¹ University of Pennsylvania School of Medicine, 116 Veteran's Affairs Virginia Medical Center/Substance Abuse Treatment Unit, Building 7, University & Woodland Avenue, Philadelphia, PA 19104, USA.

G E Woody. Curr Psychiatry Rep. 1999 Dec.

. 1999 Dec;1(2):157-8.

doi: 10.1007/s11920-999-0025-x.

G E Woody¹

¹ University of Pennsylvania School of Medicine, 116 Veteran's Affairs Virginia Medical Center/Substance Abuse Treatment Unit, Building 7, University & Woodland Avenue, Philadelphia, PA 19104, USA.

No abstract available

Similar articles

ECNP consensus meeting March 2003 guidelines for the investigation of efficacy in substance use disorders.
Van den Brink W, Montgomery SA, Van Ree JM, van Zwieten-Boot BJ; Consensus Committee. Van den Brink W, et al. Eur Neuropsychopharmacol. 2006 Apr;16(3):224-30. doi: 10.1016/j.euroneuro.2005.12.003. Epub 2006 Jan 25. Eur Neuropsychopharmacol. 2006. PMID: 16442270 No abstract available.
Endpoint considerations for clinical trials.
Walton MK. Walton MK. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3 Suppl 1:S3-6. doi: 10.1080/146608202320374129. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002. PMID: 12396791 No abstract available.
Health-related quality of life for adults participating in outpatient substance abuse treatment.
Morgan TJ, Morgenstern J, Blanchard KA, Labouvie E, Bux DA. Morgan TJ, et al. Am J Addict. 2003 May-Jun;12(3):198-210. Am J Addict. 2003. PMID: 12851016 Clinical Trial.
Novel approaches to composite endpoints in clinical trials.
Westerhout CM, Bakal JA. Westerhout CM, et al. EuroIntervention. 2015 May;11(1):122-4. doi: 10.4244/EIJV11I1A22. EuroIntervention. 2015. PMID: 25982656 No abstract available.
Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
Suman VJ, Dueck A, Sargent DJ. Suman VJ, et al. Cancer Invest. 2008 Jun;26(5):439-44. doi: 10.1080/07357900801971057. Cancer Invest. 2008. PMID: 18568764 Review. No abstract available.